With two candidate SARS-CoV-2 vaccines exhibiting high effectiveness in initial analyses, there has been a shift to wondering how vaccines, once given the regulatory go-ahead, should be distributed, the Associated Press writes.
With two candidate SARS-CoV-2 vaccines exhibiting high effectiveness in initial analyses, there has been a shift to wondering how vaccines, once given the regulatory go-ahead, should be distributed, the Associated Press writes.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.